Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Adenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL16485906 | 1.00 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL385841 | 0.88 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL14125907 | 0.86 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL28763031 | 0.86 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL9621204 | 0.86 | GDA (0.46) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL8110 | 0.84 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3413247 | 0.84 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3416954 | 0.84 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3414603 | 0.84 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL28113159 | 0.83 | APEX1 (0.40) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536532-B | Tenofovir prodrug novel polymorphic and its preparation method and application | 江苏豪森药业集团有限公司 | 2019-09-03 | — | — | CN | claimed |
| CN-110146639-A | A kind of analysis method of the novel nucleoside acids reverse transcriptase inhibitor in relation to substance | 南京正大天晴制药有限公司 | 2019-08-20 | — | — | CN | claimed |
| CN-106536532-A | New polycrystalline form of tenofovir prodrug, and preparation method and application therefor | 江苏豪森药业集团有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-105399771-A | Crystal form of tenofovir prodrug, preparation method and application of crystal form | JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO LTD | 2016-03-16 | — | — | CN | claimed |
| CN-101193642-A | Nucleotide analog prodrug and preparation thereof | BORUI BIOLOG MEDICAL TECHNOLOG (CN) | 2008-06-04 | — | — | CN | claimed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| CN-117624242-A | Purification method of tenofovir alafenamide intermediate | 上海迪赛诺化学制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117510542-A | Ai Miti norfovir fumarate spherical crystal and preparation method thereof | 天津大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-114591367-B | Continuous production method of tenofovir disoproxil fumarate | 安徽贝克制药股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-113583048-B | Tenofovir Wei Linsuan ester c crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-113683641-B | Tenofovir Wei Linsuan ester d crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-113583050-B | Tenofovir Wei Linsuan ester a crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-103211826-A | Antiviral pharmaceutical composition as well as preparation method and application thereof | FUJIAN COSUNTER PHARMACEUTICAL CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-102670629-A | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC | 2012-09-19 | — | — | CN | disclosed |
| CN-1738628-B | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC | 2012-06-06 | — | — | CN | disclosed |
| CN-101878032-A | Potent combination of zidovudine and agents selected against the K65R mutation in HIV polymerase | RFS PHARMA LLC | 2010-11-03 | — | — | CN | disclosed |
| CN-101574356-A | Tenofovir disoproxil pharmaceutical salt and preparations thereof | HEILONGJIANG CALIFORNIA INTERN (CN) | 2009-11-11 | — | — | CN | disclosed |
| CN-101066981-A | Non-cyclic nucleoside phosphonate compound and its composition, prepn process and use | SHANGHAI INST OF MEDICINES CAS (CN) | 2007-11-07 | — | — | CN | disclosed |
| CN-1938017-A | Therapeutic combinations | AGOURON PHARMA (US) | 2007-03-28 | — | — | CN | disclosed |
| CN-1738628-A | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC (US) | 2006-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | PI4KA 459/4885PI4K2B 1454/4885PI4K2A 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.